The European Commission said on Friday it had given conditional approval for the use of antiviral remdesivir in severe COVID-19 patients following an accelerated review process, making it the region's first therapy to be authorised to treat the virus.
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease , during the outbreak of the coronavirus disease , in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake
The move comes just a week after the European Medicines Agency gave its go-ahead for the drug produced by Gilead Sciences to be use in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support. “We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus,” said Stella Kyriakides, EU Commissioner for Health and Food Safety, in a statement.
A conditional marketing authorisation is one of the EU regulatory mechanisms created to facilitate early access to medicines that fulfil an unmet medical need, including those for emergency situations in response to public health threats such as the current pandemic, the Commission said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US stocks rise as COVID-19 vaccine progress offsets disappointing jobs data | Markets InsiderUS stocks rose Wednesday as investors cheered COVID-19 vaccine progress. A potential vaccine being developed by Pfizer and BioNTech spurred immu...
Read more »
Instagram’s Kevin Systrom Built A Free Covid-19 Tracking Site To Help You Make Safer DecisionsTo close-out Forbes’ Under 30 Detroit Hackathon, Kevin Systrom, a member of the inaugural Under 30 list, shared how and why he built RT.Live, his tips on starting companies to solve big problems, and the next area of tech he's looking to shake up.
Read more »
Covid-19 vaccine from Pfizer and BioNTech shows 'encouraging' data in early studyA Covid-19 vaccine candidate has yielded positive data in early tests, according to findings released by US drugmaker Pfizer and Germany's BioNTech. Follow live updates:
Read more »
Michael Yo Reflects On His Frightening Battle With COVID-19The comedian opened up to ET about his roller coaster journey from the 'AGT' stage to the hospital and how he made it through.
Read more »
COVID-19 vaccine: Pfizer vaccine shows potential in early human trialsA Pfizer COVID-19 vaccine has shown potential and was found to be well tolerated in early-stage human trials, company says. The drug is one of 17 being tested on humans, and is the 4th early-stage COVID-19 drug to show promise in human testing.
Read more »
Oxford COVID-19 vaccine developers encouraged by immune response but cautious on timeframeA leading scientist behind the University of Oxford's potential COVID-19 vaccine said on Wednesday the team has seen the right sort of immune response in trials but declined to give a firm timeframe for when it could be ready.
Read more »